{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:55:51Z","timestamp":1783702551093,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T00:00:00Z","timestamp":1591488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T00:00:00Z","timestamp":1591488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Our study aimed to map endocrine toxicity spectrum of immune checkpoint inhibitors (ICIs).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We obtained data from VigiBase, between January 1, 2011 and March 6, 2019. All endocrine adverse drug reactions (ADRs) were classified by group queries according to the Medical Dictionary for Regulatory Activities. Disproportionality analysis was performed with information component (IC) and reporting odds ratio (ROR). We used IC to identify meaningful endocrinopathies associated with ICIs and ROR to compare differences between ICI subgroups of ADRs. IC<jats:sub>025<\/jats:sub> (lower end of the 95% confidence interval of IC) is considered significant if larger than 0.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In all, 6089 reports for endocrinopathies associated with ICIs were involved, with a male to female ratio of 1.5:1. The disproportionality analysis indicated significance of not only common endocrinopathies: thyroid dysfunction, hypophysitis\/hypopituitarism, adrenal insufficiency, T1DM, fulminant T1DM (IC<jats:sub>025<\/jats:sub>: 4.12\u20136.62), but also rare endocrinopathies: hypoparathyroidism, diabetes insipidus, hypogonadism (IC<jats:sub>025<\/jats:sub>: 1.56\u20132.04). Increased risk of ADR reporting emerged in anti-CTLA-4 (e.g., hypophysitis\/hypopituitarism, adrenal insufficiency) or in anti-PD-1\/PD-L1 (e.g., thyroid dysfunction, T1DM, fulminant T1DM). In general, combination therapy (anti-CTLA-4 plus anti-PD-1\/PD-L1) had a stronger association with endocrinopathies than monotherapy (ROR: 2.8, 95% CI: 2.5\u20133.1). Onset time of common endocrinopathies differed between different ICI therapies, typically within 12 weeks in anti-CTLA-4 monotherapy but diffusely ranging from 0 to 48 weeks in anti-PD-1 monotherapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our study shows rising reporting frequencies of endocrinopathies caused by ICIs, especially aggravated in combination therapy. Clinicians should be early aware of latent endocrine toxicity and different onset time of endocrinopathies when implementing ICI therapies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s12020-020-02355-9","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T14:02:22Z","timestamp":1591538542000},"page":"670-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase"],"prefix":"10.1007","volume":"69","author":[{"given":"Xuefeng","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-730X","authenticated-orcid":false,"given":"Xiahong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kainan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,7]]},"reference":[{"key":"2355_CR1","doi-asserted-by":"publisher","first-page":"418","DOI":"10.5694\/mja16.00586","volume":"205","author":"JM Bourke","year":"2016","unstructured":"J.M. Bourke, M. O\u2019Sullivan, M.A. Khattak, Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). Med. J. Aust. 205, 418\u2013424 (2016). https:\/\/doi.org\/10.5694\/mja16.00586","journal-title":"Med. J. Aust."},{"key":"2355_CR2","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"J.R. Brahmer, C. Lacchetti, B.J. Schneider, M.B. Atkins, K.J. Brassil, J.M. Caterino et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36, 1714\u20131768 (2018). https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J. Clin. Oncol."},{"key":"2355_CR3","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"H JBAG","year":"2017","unstructured":"H. JBAG, F. Carbonnel, C. Robert, K.M. Kerr, S. Peters, J. Larkin et al., Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv119\u2013iv142 (2017). https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann. Oncol."},{"key":"2355_CR4","doi-asserted-by":"publisher","first-page":"E2560","DOI":"10.3390\/ijms20102560","volume":"20","author":"SM Ferrari","year":"2019","unstructured":"S.M. Ferrari, P. Fallahi, G. Elia, F. Ragusa, I. Ruffilli, A. Patrizio et al. Autoimmune endocrine dysfunctions associated with cancer immunotherapies. Int. J. Mol. Sci. 20, E2560 (2019). https:\/\/doi.org\/10.3390\/ijms20102560","journal-title":"Int. J. Mol. Sci."},{"key":"2355_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"L.S. Chang, R. Barroso-Sousa, S.M. Tolaney, F.S. Hodi, U.B. Kaiser, L. Min, Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40, 17\u201365 (2019). https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr. Rev."},{"key":"2355_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"M Sznol","year":"2017","unstructured":"M. Sznol, M.A. Postow, M.J. Davies, A.C. Pavlick, E.R. Plimack, M. Shaheen et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat. Rev. 58, 70\u201376 (2017). https:\/\/doi.org\/10.1016\/j.ctrv.2017.06.002","journal-title":"Cancer Treat. Rev."},{"key":"2355_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","volume":"45","author":"TK Eigentler","year":"2016","unstructured":"T.K. Eigentler, J.C. Hassel, C. Berking, J. Aberle, O. Bachmann, V. Gr\u00fcnwald et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat. Rev. 45, 7\u201318 (2016). https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.003","journal-title":"Cancer Treat. Rev."},{"key":"2355_CR8","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"D.B. Johnson, J.M. Balko, M.L. Compton, S. Chalkias, J. Gorham, Y. Xu et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749\u20131755 (2016). https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N. Engl. J. Med."},{"key":"2355_CR9","doi-asserted-by":"publisher","unstructured":"B. McMillen, M.S. Dhillon, S. Yong-Yow, A rare case of thyroid storm. BMJ Case Rep. (2016). https:\/\/doi.org\/10.1136\/bcr-2016-214603","DOI":"10.1136\/bcr-2016-214603"},{"key":"2355_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"M. Lindquist, VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf. J. 42, 409\u2013419 (2008). https:\/\/doi.org\/10.1177\/009286150804200501","journal-title":"Drug Inf. J."},{"key":"2355_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"A. Bate, M. Lindquist, I.R. Edwards, S. Olsson, R. Orre, A. Lansner et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321 (1998). https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2355_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","volume":"15","author":"PS Ang","year":"2016","unstructured":"P.S. Ang, Z. Chen, C.L. Chan, B.C. Tai, Data mining spontaneous adverse drug event reports for safety signals in Singapore\u2014a comparison of three different disproportionality measures. Expert Opin. Drug Saf. 15, 583\u2013590 (2016). https:\/\/doi.org\/10.1517\/14740338.2016.1167184","journal-title":"Expert Opin. Drug Saf."},{"key":"2355_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"G.N. Nor\u00e9n, J. Hopstadius, A. Bate, Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat. Methods Med. Res. 22, 57\u201369 (2013). https:\/\/doi.org\/10.1177\/0962280211403604","journal-title":"Stat. Methods Med. Res."},{"key":"2355_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"J.D. Wolchok, V. Chiarion-Sileni, R. Gonzalez, P. Rutkowski, J.J. Grob, C.L. Cowey et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017). https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N. Engl. J. Med."},{"key":"2355_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"18","author":"MD Hellmann","year":"2017","unstructured":"M.D. Hellmann, N.A. Rizvi, J.W. Goldman, S.N. Gettinger, H. Borghaei, J.R. Brahmer et al., Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 18, 31\u201341 (2017). https:\/\/doi.org\/10.1016\/S1470-2045(16)30624-6","journal-title":"Lancet Oncol."},{"key":"2355_CR16","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"F.S. Hodi, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, P. Rutkowski, C.L. Cowey et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19, 1480\u20131492 (2018). https:\/\/doi.org\/10.1016\/S1470-2045(18)30700-9","journal-title":"Lancet Oncol."},{"key":"2355_CR17","first-page":"1","volume":"63","author":"SJ Henley","year":"2014","unstructured":"S.J. Henley, T.B. Richards, J.M. Underwood, C.R. Eheman, M. Plescia, T.A. McAfee, Lung cancer incidence trends among men and women-United States, 2005\u20132009. MMWR Morb. Mortal. Wkly Rep. 63, 1\u20135 (2014)","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2355_CR18","first-page":"1005","volume":"28","author":"M Rastrelli","year":"2014","unstructured":"M. Rastrelli, S. Tropea, C.R. Rossi, M. Alaibac, Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 28, 1005\u20131011 (2014)","journal-title":"In Vivo."},{"key":"2355_CR19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1177\/1078155219829813","volume":"25","author":"M Lei","year":"2019","unstructured":"M. Lei, A. Michael, S. Patel, D. Wang, Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors. J. Oncol. Pharm. Pract. 25, 1402\u20131411 (2019). https:\/\/doi.org\/10.1177\/1078155219829813","journal-title":"J. Oncol. Pharm. Pract."},{"key":"2355_CR20","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"A.T. Faje, R. Sullivan, D. Lawrence, N.A. Tritos, R. Fadden, A. Klibanski et al., Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab. 99, 4078\u20134085 (2014). https:\/\/doi.org\/10.1210\/jc.2014-2306","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2355_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1089\/thy.2013.0241","volume":"23","author":"F Torino","year":"2013","unstructured":"F. Torino, A. Barnabei, R. Paragliola, R. Baldelli, M. Appetecchia, S.M. Corsello, Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 23, 1345\u20131366 (2013). https:\/\/doi.org\/10.1089\/thy.2013.0241","journal-title":"Thyroid"},{"key":"2355_CR22","doi-asserted-by":"publisher","unstructured":"X. Bai, X. Chen, X. Wu, Y. Huang, Y. Zhuang, Y. Chen, C. Feng, X Lin, Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study. J. Endocrinol. Invest. Online ahead of print (2020). https:\/\/doi.org\/10.1007\/s40618-020-01226-4","DOI":"10.1007\/s40618-020-01226-4"},{"key":"2355_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1620\/tjem.244.33","volume":"244","author":"K Sakurai","year":"2018","unstructured":"K. Sakurai, S. Niitsuma, R. Sato, K. Takahashi, Z. Arihara, Painless thyroiditis and fulminant type 1 diabetes mellitus in a patient treated with an immune checkpoint inhibitor, nivolumab. Tohoku J. Exp. Med. 244, 33\u201340 (2018). https:\/\/doi.org\/10.1620\/tjem.244.33","journal-title":"Tohoku J. Exp. Med."},{"key":"2355_CR24","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/1759-7714.13065","volume":"10","author":"R Edahiro","year":"2019","unstructured":"R. Edahiro, M. Ishijima, H. Kurebe, K. Nishida, T. Uenami, M. Kanazu et al., Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: a case report. Thorac Cancer. 10, 1276\u20131279 (2019). https:\/\/doi.org\/10.1111\/1759-7714.13065","journal-title":"Thorac Cancer."},{"key":"2355_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","volume":"13","author":"T Dillard","year":"2010","unstructured":"T. Dillard, C.G. Yedinak, J. Alumkal, M. Fleseriu, Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13, 29\u201338 (2010). https:\/\/doi.org\/10.1007\/s11102-009-0193-z","journal-title":"Pituitary"},{"key":"2355_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1210\/jc.2017-01905","volume":"103","author":"C Zhao","year":"2018","unstructured":"C. Zhao, S.H. Tella, J. Del Rivero, A. Kommalapati, I. Ebenuwa, J. Gulley et al. Anti-PD-L1 treatment induced central diabetes insipidus. J. Clin. Endocrinol. Metab. 103, 365\u2013369 (2018). https:\/\/doi.org\/10.1210\/jc.2017-01905","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2355_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","volume":"7","author":"B Trinh","year":"2019","unstructured":"B. Trinh, G.O. Sanchez, P. Herzig, H. L\u00e4ubli, Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. J. Immunother. Cancer 7, 52 (2019). https:\/\/doi.org\/10.1186\/s40425-019-0528-x","journal-title":"J. Immunother. Cancer"},{"key":"2355_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1210\/jc.2018-01151","volume":"104","author":"P Piranavan","year":"2019","unstructured":"P. Piranavan, Y. Li, E. Brown, E.H. Kemp, N. Trivedi, Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J. Clin. Endocrinol. Metab. 104, 550\u2013556 (2019). https:\/\/doi.org\/10.1210\/jc.2018-01151","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2355_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-19-0535","volume":"182","author":"X Bai","year":"2020","unstructured":"X. Bai, X. Chen, X. Wu, Y. Huang, Y. Zhuang, X. Lin, Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO adverse drug reaction database VigiBase. Eur. J. Endocrinol. 182, 1\u20139 (2020). https:\/\/doi.org\/10.1530\/EJE-19-0535","journal-title":"Eur. J. Endocrinol."},{"key":"2355_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"D.J. Byun, J.D. Wolchok, L.M. Rosenberg, M. Girotra, Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol. 13, 195\u2013207 (2017). https:\/\/doi.org\/10.1038\/nrendo.2016.205","journal-title":"Nat. Rev. Endocrinol."},{"key":"2355_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"C. Boutros, A. Tarhini, E. Routier, O. Lambotte, F.L. Ladurie, F. Carbonnel et al., Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473\u2013486 (2016). https:\/\/doi.org\/10.1038\/nrclinonc.2016.58","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2355_CR32","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"A.M. Stamatouli, Z. Quandt, A.L. Perdigoto, P.L. Clark, H. Kluger, S.A. Weiss et al., Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 67, 1471\u20131480 (2018). https:\/\/doi.org\/10.2337\/dbi18-0002","journal-title":"Diabetes."},{"key":"2355_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro, F.S. Hodi, L. Min, I.E. Krop et al., Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 4, 173\u2013182 (2018). https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol."},{"key":"2355_CR34","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/CMR.0000000000000384","volume":"27","author":"A Tsiogka","year":"2017","unstructured":"A. Tsiogka, G.L. Jansky, J.W. Bauer, P. Koelblinger, Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma. Melanoma Res. 27, 524\u2013525 (2017). https:\/\/doi.org\/10.1097\/CMR.0000000000000384","journal-title":"Melanoma Res."},{"key":"2355_CR35","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00280-015-2873-x","volume":"76","author":"N Yamazaki","year":"2015","unstructured":"N. Yamazaki, Y. Kiyohara, H. Uhara, S. Fukushima, H. Uchi, N. Shibagaki et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother. Pharmacol. 76, 997\u20131004 (2015). https:\/\/doi.org\/10.1007\/s00280-015-2873-x","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2355_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/jdi.12119","volume":"5","author":"E Kawasaki","year":"2014","unstructured":"E. Kawasaki, T. Maruyama, A. Imagawa, T. Awata, H. Ikegami, Y. Uchigata et al., Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): report of the Committee of Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus. J. Diabetes Investig. 5, 115\u2013118 (2014). https:\/\/doi.org\/10.1111\/jdi.12119","journal-title":"J. Diabetes Investig."},{"key":"2355_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"F. Martins, L. Sofiya, G.P. Sykiotis, F. Lamine, M. Maillard, M. Fraga et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019). https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2355_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"J.C. Hassel, L. Heinzerling, J. Aberle, O. B\u00e4hr, T.K. Eigentler, M.O. Grimm et al. Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat. Rev. 57, 36\u201349 (2017). https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.003","journal-title":"Cancer Treat. Rev."},{"key":"2355_CR39","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"J.E. Salem, A. Manouchehri, M. Moey, B. Lebrun-Vignes, L. Bastarache, A. Pariente et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 19, 1579\u20131589 (2018). https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol."},{"key":"2355_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"D.B. Johnson, A. Manouchehri, A.M. Haugh, H.T. Quach, J.M. Balko, B. Lebrun-Vignes et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J. Immunother. Cancer 7, 134 (2019). https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J. Immunother. Cancer"},{"key":"2355_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"V. Sibaud, Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am. J. Clin. Dermatol. 19, 345\u2013361 (2018). https:\/\/doi.org\/10.1007\/s40257-017-0336-3","journal-title":"Am. J. Clin. Dermatol."},{"key":"2355_CR42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402\u00d7.2017","volume":"6","author":"DY Wang","year":"2017","unstructured":"D.Y. Wang, F. Ye, S. Zhao, D.B. Johnson, Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology 6, e1344805 (2017). https:\/\/doi.org\/10.1080\/2162402\u00d7.2017","journal-title":"Oncoimmunology"},{"key":"2355_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.13063","volume":"85","author":"MN Joshi","year":"2016","unstructured":"M.N. Joshi, B.C. Whitelaw, M.T. Palomar, Y. Wu, P.V. Carroll, Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin. Endocrinol. 85, 331\u2013339 (2016). https:\/\/doi.org\/10.1111\/cen.13063","journal-title":"Clin. Endocrinol."},{"key":"2355_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"L. Spain, S. Diem, J. Larkin, Management of toxicities of immune checkpoint inhibitors. Cancer Treat. Rev. 44, 51\u201360 (2016). https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat. Rev."},{"key":"2355_CR45","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2169\/internalmedicine.9518-17","volume":"57","author":"M Shiba","year":"2018","unstructured":"M. Shiba, H. Inaba, H. Ariyasu, S. Kawai, Y. Inagaki, S. Matsuno et al., Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-ctla-4 antibody following the discontinuation of anti-pd-1 antibody. Intern. Med. 57, 2029\u20132034 (2018). https:\/\/doi.org\/10.2169\/internalmedicine.9518-17","journal-title":"Intern. Med."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02355-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-020-02355-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02355-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:01:56Z","timestamp":1623024116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-020-02355-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,7]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2355"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02355-9","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,7]]},"assertion":[{"value":"12 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}